Bromfenac-d4 (sodium salt) |
| Catalog No.GC46951 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2749400-35-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Bromfenac-d4 is intended for use as an internal standard for the quantification of bromfenac by GC- or LC-MS. Bromfenac is an inhibitor of cyclooxygenase 2 (COX-2; IC50 = 6.6 nM) that is selective over COX-1 (IC50 = 210 nM).1 It inhibits prostaglandin E2 production in a rabbit model of LPS-induced eye inflammation. Bromfenac also decreases inflammation following cataract removal in dogs when administered as a 0.9% topical solution on a tapering schedule for 24 weeks.2 Formulations containing bromfenac have been used in the treatment of postoperative inflammation following cataract surgery.
1.Waterbury, L.D., Silliman, D., and Jolas, T.Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodiumCurr. Med. Res. Opin.22(6)1133-1140(2006) 2.Brookshire, H.L., English, R.V., Nadelstein, B., et al.Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removalVet. Ophthalmol.18(3)175-185(2015)
Average Rating: 5 (Based on Reviews and 17 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *